Articles - Page 57 of 96 - Drugs in Context

Temozolomide and oral etoposide in children with recurrent malignant brain tumors

Antonio Ruggiero MD, Anna Ariano MD, Silvia Triarico MD, Michele Antonio Capozza MD, Alberto Romano MD, Palma Maurizi MD, Stefano Mastrangelo MD, Giorgio Attinà MD

Article Type

Review

Published

02 Jun 2020

The article reviews the results
derived from the combination use of TMZ and oral VP-16 to treat malignant brain tumors

A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic

Matteo Bassetti MD, PhD, Paolo Pelosi MD, FERS, Chiara Robba MD, PhD, Antonio Vena MD, PhD, Daniele Roberto Giacobbe MD

Article Type

Editorial

Published

26 May 2020

Randomized controlled trials (RCTs) are the best way to find effective and acceptable safe treatments for COVID-19 and any possible future outbreak. However, caution is needed when comparing the number of participants in RCTs with that of patients with COVID-19 treated with compassionate and/or off-label drugs to support the hypothesis that the latter are preferred by clinicians as an alternative to the former.

Antidepressant efficacy and side effect burden: an updated guide for clinicians

Tatum Kutzer DO, Michelle Dick MD, Trevor Scudamore MD, Mark Wiener MD, Thomas Schwartz MD

Article Type

Review

Published

26 May 2020

This article serves to provide clinicians with updated information about novel antidepressant medications, augmentation strategies with atypical antipsychotics, over-the-counter medications, as well as nonpharmaceutical treatments that should be considered when treating each individual patient who remains symptomatic despite treatment efforts.

The journey of remdesivir: from Ebola to COVID-19

Joe Pardo PharmD, Ashutosh M Shukla MD, Gajapathiraju Chamarthi MD, Asmita Gupte MD

Article Type

Review

Published

22 May 2020

In this narrative review, an overview of Ebola and coronavirus outbreaks is provided as well as a summary of preclinical and clinical studies of remdesivir for Ebola and COVID-19.

Overcoming hurdles: measurement of health-related outcomes associated with national level medicines usage in Ireland

Gary L O’Brien BPharm, MPharm, Muireann McAlister BSc Pharmacy, Stephen Byrne BSc Pharmacy, PhD, James Gallagher BPharm, MPharm, PhD

Article Type

Editorial

Published

22 May 2020

This editorial provides an overview of the evolving healthcare landscape surrounding medicine usage estimation and valuation in Ireland and offers recommendations on how improved methods of measuring health-related outcomes may help ameliorate efficiencies and the sustainability of a healthcare system.